Success Metrics

Active Trials

2(50%)

Phase Distribution

Ph phase_1

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Recruiting2

Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

recruiting250%

not_yet_recruiting250%

Recent Activity

2 active trials

Showing 4 of 4

recruitingphase_1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

NCT06714591

not_yet_recruitingphase_1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

NCT07591168

not_yet_recruitingphase_2

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

NCT07255872

recruitingphase_1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05924750

Clinical Trials (4)

Showing 4 of 4 trials

NCT06714591Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Recruiting

NCT07591168Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

Not Yet Recruiting

NCT07255872Phase 2

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Not Yet Recruiting

NCT05924750Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4